Regenold and colleagues [ 40] found that an index of treatment resistance correlated significantly with deep white matter hyperintensity volume, as well as measures of abnormal brain glucose metabolism (sorbitol and fructose) in bipolar patients but not in other patients (i.e, those with schizophrenia and neurologic controls).
Control subjects, including both non-neurologic controls and Alzheimer's disease, exhibited a punctate or speckled RBM45 pattern within the nucleus of dentate granule cells (Fig. 3a c).
In order to assess the diagnostic utility of cystatin C, we first compared the mean first-draw cystatin C levels among ALS patients, neurologic disease controls, and healthy controls.
CSF and plasma samples were collected at the same office visit every four to six months from 44 ALS patients (2 8 draws), and either once or twice (1.5 2 years apart) from 35 non-neurologic healthy controls (HC) and 25 neurologic disease controls (DC).
Cystatin C levels in ALS patients were significantly elevated in plasma and reduced in CSF compared to healthy controls, but did not differ significantly from neurologic disease controls.
We compared anti-HHV-6 IgG levels in the CSF between other neurologic disease controls (OND, Table S1), patients with suspected viral encephalitis, untreated MS patients (a subset of the NIH cohort), and patients with infectious complications post-bone marrow transplant (BMT) [31].
Finally, we detected no RBM45 pathology in the hippocampus of any non-neurologic disease control case.
Paraffin-embedded tissue sections of spinal cord from ALS (n = 23), FTLD-TDP (n = 2), and non-neurologic disease control (n = 7), and hippocampus from ALS (n = 9), FTLD-TDP (n = 6), Alzheimer's disease (n = 4) and non-neurologic disease control (n = 5) cases were used for this study.
Since our previous studies showed increased expression of HDAC3 in MS patients over that seen in controls and HDAC3 expression is linked with the expression of proinflammatory cytokines, we set out to examine the relationship between the expression of HDAC3 and IL-33 in MS and compared them with other neurologic disease controls.
CSF samples from non-neurologic disease controls (n = 9) and ALS (n = 9) were analyzed for immunoblot.
